SCHEMBL1997193

SCHEMBL1997193

CC(C)CN1C(=O)CN(Cc2ccc(-c3cc(F)cc(CN4CCCCC4)c3)cc2)C1=O

nearest known ligand 0.46

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 7/20 0.46
HRH4 Q9H3N8 1/20 0.41
DYRK1A Q13627 4/20 0.40
MCHR1 Q99705 3/20 0.39
HTR2C P28335 1/20 0.39
WNT1 P04628 2/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
ENPP2 Q13822 2/20 0.39
ALDH1A1 P00352 2/20 0.38
CHKA P35790 1/20 0.38
HTT P42858 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1998795 0.86 CYP2D6 (0.49) HRH3HRH4MCHR1CYP2D6CYP2C19
SCHEMBL1997243 0.84 HRH3 (0.44) HRH3HRH4MCHR1HTR2CCYP2D6
SCHEMBL1997569 0.80 CYP2D6 (0.49) HRH3HRH4MCHR1HTR2CCYP2D6
SCHEMBL2001267 0.79 CHKA (0.41) HRH3HRH4DYRK1AWNT1CYP2D6
SCHEMBL840172 0.76 HRH3 (0.41) HRH3HRH4CYP2D6CYP2C19ENPP2
SCHEMBL2002675 0.76 DHODH (0.43) HRH3CYP2D6CYP2C19ENPP2
SCHEMBL2000696 0.75 WDR5 (0.41) HRH3CHKA
SCHEMBL1995456 0.75 LRRK2 (0.41) HRH3CYP2D6CYP2C19ENPP2
SCHEMBL2001890 0.74 KMT2A (0.37) HRH3ENPP2
SCHEMBL840270 0.72 ALDH1A1 (0.38) DYRK1AALDH1A1CHKAHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US claimed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US claimed
EP-2373627-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. Organon (NL) 2011-10-12 EP disclosed
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US disclosed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US disclosed
WO-2010063721-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. ORGANON (NL) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE OPRM1, OR10J3, OPRD1 HRH3 32/4885HRH4 8/4885DYRK1A 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.